Suche senden
Hochladen
Vital Signs Edition #6
•
Als DOCX, PDF herunterladen
•
1 gefällt mir
•
1,060 views
S
ScottJordan
Folgen
Technologie
Gesundheit & Medizin
Melden
Teilen
Melden
Teilen
1 von 16
Jetzt herunterladen
Empfohlen
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Fundación Ramón Areces
CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawa
spa718
CAR-T Pipeline, CAR-T Clinical Trails, CAR-T Drugs, CAR-T Therapy, CAR-T Treatment, CAR-T Emerging Drugs CAR-T Pipeline Drugs, CAR-T Companies, CAR-T Pipeline Companies,
What is car t pipeline
What is car t pipeline
DelveInsight Business Research
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Melanoma Immunotherapy - Dr. Patrick Hwu
Melanoma Immunotherapy - Dr. Patrick Hwu
Melanoma Research Foundation
Final presentation for BIOL405, NSC, Spring 2014. Presented by Kevin Hugins and Duy-Khiem Chanh Pham. This presentation addressed the use of Chimeric Antigen Receptors for gene therapy for cancer. Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Chimeric Antigen Receptors
Chimeric Antigen Receptors
Kevin B Hugins
These slides provide an overview of 100 therapeutic cancer vaccines in development, a look at some of the failures, what's been and is being done to address the clinical development of these vaccines and a snapshot of some deals, terms and the number of companies seeking commercializations partners.
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Michael Sheckler
Key translational research concept illustrated by personal experiences
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
tsornasse
Inmunoterapia en cáncer de pulmón
2015 11 Inmunoterapia en nsclc
2015 11 Inmunoterapia en nsclc
Martín Lázaro
Empfohlen
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Fundación Ramón Areces
CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawa
spa718
CAR-T Pipeline, CAR-T Clinical Trails, CAR-T Drugs, CAR-T Therapy, CAR-T Treatment, CAR-T Emerging Drugs CAR-T Pipeline Drugs, CAR-T Companies, CAR-T Pipeline Companies,
What is car t pipeline
What is car t pipeline
DelveInsight Business Research
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Melanoma Immunotherapy - Dr. Patrick Hwu
Melanoma Immunotherapy - Dr. Patrick Hwu
Melanoma Research Foundation
Final presentation for BIOL405, NSC, Spring 2014. Presented by Kevin Hugins and Duy-Khiem Chanh Pham. This presentation addressed the use of Chimeric Antigen Receptors for gene therapy for cancer. Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Chimeric Antigen Receptors
Chimeric Antigen Receptors
Kevin B Hugins
These slides provide an overview of 100 therapeutic cancer vaccines in development, a look at some of the failures, what's been and is being done to address the clinical development of these vaccines and a snapshot of some deals, terms and the number of companies seeking commercializations partners.
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Therapeutic Cancer Vaccines: A Future of Possibilities Haunted By A History o...
Michael Sheckler
Key translational research concept illustrated by personal experiences
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
tsornasse
Inmunoterapia en cáncer de pulmón
2015 11 Inmunoterapia en nsclc
2015 11 Inmunoterapia en nsclc
Martín Lázaro
SciTech’s lead compound, ST-001, is a small-molecule immune oncology (IO) nanoFenretinide cancer drug employed as an aqueous nanoparticle suspension for IV administration. The ST-001 nanoFenretinide drug is comprised of the active pharmaceutical ingredient (API) fenretinide in a patented combination with carefully selected phospholipids (inactive ingredients). ST-001 is designed to deliver a 15-fold higher drug to lipid ratio and a >6x concentration of the API than conventional IV formulations achieving therapeutically effective doses without the toxic side effects observed with other delivery systems – a benefit previously unattainable. Recent discovery of the API’s immunotherapeutic effect, in which a reactivated natural immune response compliments the previously understood safe, direct, chemotherapeutic effect (functioning as dual mechanisms of action), has added materially to its value as a versatile therapeutic.
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
SciTech Development
Canadian Expert Patients in Health Technology Conference Nov 7 – 8, 2016: Day 1
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Canadian Organization for Rare Disorders
Next Generation Sequencing
Vital Signs Edition #3
Vital Signs Edition #3
ScottJordan
Targeted h& n
Targeted h& n
dmtudtud
SciTech Development pitch deck including company overview, proprietary technology, lead drug ST-001 nanoFenretinide, patents, addressable market sizes, competiton, key personnel, advisory board, drug product characteristics, fenretinide history, cancer indications and drug mechanism of action (MOA).
SciTech Development Company Presentation
SciTech Development Company Presentation
SciTech Development
Basic immunology of colorectal cancer. Highlight the future role of immunotherapy in Colorectal cancer.
Basics of immunotherapy in colorectal cancer
Basics of immunotherapy in colorectal cancer
Mohamed Abdulla
T cell Therapy basics
Car t cell basics cell therapy working group 11.21.19
Car t cell basics cell therapy working group 11.21.19
Miomir Knežević
Basic knowledge the physician should know about immunotherapy
Immunotherapy a clinician's perspective
Immunotherapy a clinician's perspective
Mohamed Abdulla
SciTech Development LLC - Intelligent Technology to Solve Unmet Clinical Needs - Often the difference between success and failure is the dedication and persistence of the executive team. SciTech Development’s principal asset, fenretinide, is guided by a deeply experienced team in the broad portfolio of pharmaceutical development, clinical strategy, and scientific formulation.
SciTech Development Testamonial Brochure
SciTech Development Testamonial Brochure
SciTech Development
Learn more about how AARSOTA Bio-Immunotherapy integrates with Hope4Cancer's non-toxic cancer treatment strategies. Hope4Cancer's alternative cancer treatments reduces the toxic effects of prior chemo and radiation treatments while directly healing the cancer.
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
Subrata Chakravarty
Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)
Kevin B Hugins
Avastin - Anti-Angiogenic or Vascular Permeability Factor
Vital Signs Edition #2
Vital Signs Edition #2
ScottJordan
This presentation was made for Journal club session about 2017 article from Journal of cancer immunotherapy. It reveals a new method of chemokine receptor gene modification on NK cells to improve their migration into tumor site. Such modification helps us to "cheat" tumor by changing the pattern of immune cells homing.
Journal club_NKs CXCR2 gene modified - improved migration
Journal club_NKs CXCR2 gene modified - improved migration
Ihor Arkhypov
Andre Radensky's Sigma Xi Showcase slideshare on T-cell immunotherapy and the chimeric antigen receptor
Andre Radensky Sigma Xi
Andre Radensky Sigma Xi
aradensky
Dendreon.Final
Dendreon.Final
sarahmerlen
Evan J. Lipson, MD, Andrew Stolbach, MD, MPH, and Trish Brothers, BSN, RN, OCN®, prepared useful practice aids pertaining to oncologic emergencies for this CME/MOC/CNE/CPE activity titled "Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2TGpnYl. CME/MOC/CNE/CPE credit will be available until February 21, 2020.
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
PVI, PeerView Institute for Medical Education
Types of immunotherapy Oncology cancer vaccines adoptive T cell transfer oncolytic viruses monoclonal antibodies cytokine treatment of cancer with immunotherapy
Immunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitors
Gaurav Kumar
Currently, ADC drug research has experienced a pile-up of targets, overlapping indication layouts and similar forms. There is an urgent need for a number of manufacturers to come up with new ideas to solve the existing problems. Some companies have taken an alternative route and laid out peptide-drug conjugate (PDC), which is relatively less competitive.
Anti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overview
DoriaFang
Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear.
Overexpression of YAP 1 contributes to progressive features and poor prognosi...
Overexpression of YAP 1 contributes to progressive features and poor prognosi...
Enrique Moreno Gonzalez
Provenge (sipuleucel t)
Provenge (sipuleucel t)
Vinblast
Medical Tourism
Research Document 3674
Research Document 3674
ScottJordan
SJA Destination Club White Paper
SJA Destination Club White Paper
ScottJordan
Weitere ähnliche Inhalte
Was ist angesagt?
SciTech’s lead compound, ST-001, is a small-molecule immune oncology (IO) nanoFenretinide cancer drug employed as an aqueous nanoparticle suspension for IV administration. The ST-001 nanoFenretinide drug is comprised of the active pharmaceutical ingredient (API) fenretinide in a patented combination with carefully selected phospholipids (inactive ingredients). ST-001 is designed to deliver a 15-fold higher drug to lipid ratio and a >6x concentration of the API than conventional IV formulations achieving therapeutically effective doses without the toxic side effects observed with other delivery systems – a benefit previously unattainable. Recent discovery of the API’s immunotherapeutic effect, in which a reactivated natural immune response compliments the previously understood safe, direct, chemotherapeutic effect (functioning as dual mechanisms of action), has added materially to its value as a versatile therapeutic.
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
SciTech Development
Canadian Expert Patients in Health Technology Conference Nov 7 – 8, 2016: Day 1
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Canadian Organization for Rare Disorders
Next Generation Sequencing
Vital Signs Edition #3
Vital Signs Edition #3
ScottJordan
Targeted h& n
Targeted h& n
dmtudtud
SciTech Development pitch deck including company overview, proprietary technology, lead drug ST-001 nanoFenretinide, patents, addressable market sizes, competiton, key personnel, advisory board, drug product characteristics, fenretinide history, cancer indications and drug mechanism of action (MOA).
SciTech Development Company Presentation
SciTech Development Company Presentation
SciTech Development
Basic immunology of colorectal cancer. Highlight the future role of immunotherapy in Colorectal cancer.
Basics of immunotherapy in colorectal cancer
Basics of immunotherapy in colorectal cancer
Mohamed Abdulla
T cell Therapy basics
Car t cell basics cell therapy working group 11.21.19
Car t cell basics cell therapy working group 11.21.19
Miomir Knežević
Basic knowledge the physician should know about immunotherapy
Immunotherapy a clinician's perspective
Immunotherapy a clinician's perspective
Mohamed Abdulla
SciTech Development LLC - Intelligent Technology to Solve Unmet Clinical Needs - Often the difference between success and failure is the dedication and persistence of the executive team. SciTech Development’s principal asset, fenretinide, is guided by a deeply experienced team in the broad portfolio of pharmaceutical development, clinical strategy, and scientific formulation.
SciTech Development Testamonial Brochure
SciTech Development Testamonial Brochure
SciTech Development
Learn more about how AARSOTA Bio-Immunotherapy integrates with Hope4Cancer's non-toxic cancer treatment strategies. Hope4Cancer's alternative cancer treatments reduces the toxic effects of prior chemo and radiation treatments while directly healing the cancer.
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
Subrata Chakravarty
Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)
Kevin B Hugins
Avastin - Anti-Angiogenic or Vascular Permeability Factor
Vital Signs Edition #2
Vital Signs Edition #2
ScottJordan
This presentation was made for Journal club session about 2017 article from Journal of cancer immunotherapy. It reveals a new method of chemokine receptor gene modification on NK cells to improve their migration into tumor site. Such modification helps us to "cheat" tumor by changing the pattern of immune cells homing.
Journal club_NKs CXCR2 gene modified - improved migration
Journal club_NKs CXCR2 gene modified - improved migration
Ihor Arkhypov
Andre Radensky's Sigma Xi Showcase slideshare on T-cell immunotherapy and the chimeric antigen receptor
Andre Radensky Sigma Xi
Andre Radensky Sigma Xi
aradensky
Dendreon.Final
Dendreon.Final
sarahmerlen
Evan J. Lipson, MD, Andrew Stolbach, MD, MPH, and Trish Brothers, BSN, RN, OCN®, prepared useful practice aids pertaining to oncologic emergencies for this CME/MOC/CNE/CPE activity titled "Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2TGpnYl. CME/MOC/CNE/CPE credit will be available until February 21, 2020.
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
PVI, PeerView Institute for Medical Education
Types of immunotherapy Oncology cancer vaccines adoptive T cell transfer oncolytic viruses monoclonal antibodies cytokine treatment of cancer with immunotherapy
Immunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitors
Gaurav Kumar
Currently, ADC drug research has experienced a pile-up of targets, overlapping indication layouts and similar forms. There is an urgent need for a number of manufacturers to come up with new ideas to solve the existing problems. Some companies have taken an alternative route and laid out peptide-drug conjugate (PDC), which is relatively less competitive.
Anti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overview
DoriaFang
Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear.
Overexpression of YAP 1 contributes to progressive features and poor prognosi...
Overexpression of YAP 1 contributes to progressive features and poor prognosi...
Enrique Moreno Gonzalez
Provenge (sipuleucel t)
Provenge (sipuleucel t)
Vinblast
Was ist angesagt?
(20)
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Developments in precision/personalized therapies: Robert Petit (Advaxis)
Vital Signs Edition #3
Vital Signs Edition #3
Targeted h& n
Targeted h& n
SciTech Development Company Presentation
SciTech Development Company Presentation
Basics of immunotherapy in colorectal cancer
Basics of immunotherapy in colorectal cancer
Car t cell basics cell therapy working group 11.21.19
Car t cell basics cell therapy working group 11.21.19
Immunotherapy a clinician's perspective
Immunotherapy a clinician's perspective
SciTech Development Testamonial Brochure
SciTech Development Testamonial Brochure
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)
Vital Signs Edition #2
Vital Signs Edition #2
Journal club_NKs CXCR2 gene modified - improved migration
Journal club_NKs CXCR2 gene modified - improved migration
Andre Radensky Sigma Xi
Andre Radensky Sigma Xi
Dendreon.Final
Dendreon.Final
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Immunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitors
Anti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overview
Overexpression of YAP 1 contributes to progressive features and poor prognosi...
Overexpression of YAP 1 contributes to progressive features and poor prognosi...
Provenge (sipuleucel t)
Provenge (sipuleucel t)
Andere mochten auch
Medical Tourism
Research Document 3674
Research Document 3674
ScottJordan
SJA Destination Club White Paper
SJA Destination Club White Paper
ScottJordan
Vital Signs Edition #5
Vital Signs Edition #5
ScottJordan
Avastin
Vital Signs Edition #1
Vital Signs Edition #1
ScottJordan
Vital Signs Edition #4
Vital Signs Edition #4
ScottJordan
Reserve Collection Tombstone
Reserve Collection Tombstone
ScottJordan
Pain as 5th vital sign eng bro
Pain as 5th vital sign eng bro
Lee Oi Wah
Andere mochten auch
(7)
Research Document 3674
Research Document 3674
SJA Destination Club White Paper
SJA Destination Club White Paper
Vital Signs Edition #5
Vital Signs Edition #5
Vital Signs Edition #1
Vital Signs Edition #1
Vital Signs Edition #4
Vital Signs Edition #4
Reserve Collection Tombstone
Reserve Collection Tombstone
Pain as 5th vital sign eng bro
Pain as 5th vital sign eng bro
Ähnlich wie Vital Signs Edition #6
Tugas Terapi gen
Gene therapy for the treatmen of cancer
Gene therapy for the treatmen of cancer
grachea aeryndhien
The future development of ADCs includes more new targets, new mechanisms of action, and new forms.
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
A brief review of Cancer Vaccines
Cancer immunotherapy slideshare
Cancer immunotherapy slideshare
Nu Powell
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology And
drmisbah83
Immuno-oncology Discoveries, University of Chicago
Immuno-oncology Discoveries, University of Chicago
uchicagotech
WP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final edits
Chris Learn, Ph.D, PMP
tumor microenviroment tumor escape mechanism] chekmate 141 keynote-012 head and neck cancer cystic fibrosis oncolytic virus
Immunotherapy and gene therapy
Immunotherapy and gene therapy
ashish gupta
Exciting progress has been made in the development and application of new therapeutic antibodies, such as ADCs, ARCs.
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
DoriaFang
T cell therapy
Engineered T Cell Therapy for Gynecologic Malignancies Challenges and Opportu...
Engineered T Cell Therapy for Gynecologic Malignancies Challenges and Opportu...
RudrikaChandra1
Humanized mice for Immuno-Oncology. A guide to everything you need to know about tumor-bearing hu-NSG.
Immuno oncology wp
Immuno oncology wp
The Jackson Laboratory
Immunotherapeutic drugs can be broadly classified into four types: checkpoint inhibitors, cytokines, monoclonal antibodies, and vaccines. However, immunotherapeutic drugs still have some problems, such as off-target side effects and poor pharmacokinetics.
Nanomedicine based cancer immunotherapy
Nanomedicine based cancer immunotherapy
DoriaFang
Cancer–testis antigens (CTA) comprise a family of proteins, which are physiologically expressed in adult human tissues solely in testicular germ cells and occasionally placenta. However, CTA expression has been reported in various malignancies. CTAs have been identified by their ability to elicit autologous cellular and or serological immune responses, and are considered potential targets for cancer immunotherapy. The breast differentiation antigen NY-BR-1, expressed specifically in normal and malignant breast tissue, has also immunogenic properties. Here we evaluated the expression patterns of CTAs and NY-BR-1 in breast cancer in correlation to clinico-pathological parameters in order to determine their possible impact as prognostic factors.
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prog...
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prog...
Enrique Moreno Gonzalez
Thesis section...Non-surgical management of brain tumors http://yassermetwally.com http://yassermetwally.net
Presentation...Non-surgical management of brain tumors
Presentation...Non-surgical management of brain tumors
Professor Yasser Metwally
inmunoterapia
Pham2018
Pham2018
Francisco Javier Martínez Hernandez
KIYATEC_Advanced_IO_CoCulture
KIYATEC_Advanced_IO_CoCulture
☤ Bryce Chaney, MBA
KIYATEC-Advanced-CoCulture-LRes
KIYATEC-Advanced-CoCulture-LRes
☤ Bryce Chaney, MBA
T cells genetically engineered to express chimeric antigen receptors (CAR) have proven an impressive therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. However, in patients with solid tumors, objective responses to CAR-T cell therapy remain sporadic and transient. Key challenges relating to CAR T cells include the lack of tumor exclusive target, restricted CAR-T cell trafficking to tumor sites, antigen escape and heterogeneity as well as a highly immunosuppressive microenvironment. In this report, we review the current state of the CAR-T technologies as a clinical treatment in solid tumor and we highlight the preclinical innovative designs of novel CAR T cell products that are being developed to increase and expand the clinical benefits of these treatments in patients with solid malignancies.
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORS
Claire Roudot
April 2017 Corporate Presentation
April 2017 Corporate Presentation
April 2017 Corporate Presentation
oncolyticsinc
Galena presentation 8 feb 16
Galena presentation 8 feb 16
Galena presentation 8 feb 16
Galenabio
Review of Adoptive T-Cell Immunotherapy
Review of Adoptive T-Cell Immunotherapy
Luke Brennan
Ähnlich wie Vital Signs Edition #6
(20)
Gene therapy for the treatmen of cancer
Gene therapy for the treatmen of cancer
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
Cancer immunotherapy slideshare
Cancer immunotherapy slideshare
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Immuno-oncology Discoveries, University of Chicago
Immuno-oncology Discoveries, University of Chicago
WP_ClinDev-Immunotherapy_d03-final edits
WP_ClinDev-Immunotherapy_d03-final edits
Immunotherapy and gene therapy
Immunotherapy and gene therapy
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Engineered T Cell Therapy for Gynecologic Malignancies Challenges and Opportu...
Engineered T Cell Therapy for Gynecologic Malignancies Challenges and Opportu...
Immuno oncology wp
Immuno oncology wp
Nanomedicine based cancer immunotherapy
Nanomedicine based cancer immunotherapy
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prog...
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prog...
Presentation...Non-surgical management of brain tumors
Presentation...Non-surgical management of brain tumors
Pham2018
Pham2018
KIYATEC_Advanced_IO_CoCulture
KIYATEC_Advanced_IO_CoCulture
KIYATEC-Advanced-CoCulture-LRes
KIYATEC-Advanced-CoCulture-LRes
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORS
April 2017 Corporate Presentation
April 2017 Corporate Presentation
Galena presentation 8 feb 16
Galena presentation 8 feb 16
Review of Adoptive T-Cell Immunotherapy
Review of Adoptive T-Cell Immunotherapy
Kürzlich hochgeladen
Dubai, known for its towering skyscrapers, luxurious lifestyle, and relentless pursuit of innovation, often finds itself in the global spotlight. However, amidst the glitz and glamour, the emirate faces its own set of challenges, including the occasional threat of flooding. In recent years, Dubai has experienced sporadic but significant floods, disrupting normalcy and posing unique challenges to its infrastructure. Among the critical nodes in this bustling metropolis is the Dubai International Airport, a vital hub connecting the world. This article delves into the intersection of Dubai flood events and the resilience demonstrated by the Dubai International Airport in the face of such challenges.
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Orbitshub
Presented by Mike Hicks
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
ThousandEyes
Scaling API-first – The story of a global engineering organization Ian Reasor, Senior Computer Scientist - Adobe Radu Cotescu, Senior Computer Scientist - Adobe Apidays New York 2024: The API Economy in the AI Era (April 30 & May 1, 2024) ------ Check out our conferences at https://www.apidays.global/ Do you want to sponsor or talk at one of our conferences? https://apidays.typeform.com/to/ILJeAaV8 Learn more on APIscene, the global media made by the community for the community: https://www.apiscene.io Explore the API ecosystem with the API Landscape: https://apilandscape.apiscene.io/
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
apidays
In this talk, we are going to cover the use-case of food image generation at Delivery Hero, its impact and the challenges. In particular, we will present our image scoring solution for filtering out inappropriate images and elaborate on the models we are using.
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
Zilliz
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
Nanddeep Nachan
Angeliki Cooney has spent over twenty years at the forefront of the life sciences industry, working out of Wynantskill, NY. She is highly regarded for her dedication to advancing the development and accessibility of innovative treatments for chronic diseases, rare disorders, and cancer. Her professional journey has centered on strategic consulting for biopharmaceutical companies, facilitating digital transformation, enhancing omnichannel engagement, and refining strategic commercial practices. Angeliki's innovative contributions include pioneering several software-as-a-service (SaaS) products for the life sciences sector, earning her three patents. As the Senior Vice President of Life Sciences at Avenga, Angeliki orchestrated the firm's strategic entry into the U.S. market. Avenga, a renowned digital engineering and consulting firm, partners with significant entities in the pharmaceutical and biotechnology fields. Her leadership was instrumental in expanding Avenga's client base and establishing its presence in the competitive U.S. market.
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Angeliki Cooney
Passkeys: Developing APIs to enable passwordless authentication Cody Salas, Sr Developer Advocate | Solutions Architect - Yubico Apidays New York 2024: The API Economy in the AI Era (April 30 & May 1, 2024) ------ Check out our conferences at https://www.apidays.global/ Do you want to sponsor or talk at one of our conferences? https://apidays.typeform.com/to/ILJeAaV8 Learn more on APIscene, the global media made by the community for the community: https://www.apiscene.io Explore the API ecosystem with the API Landscape: https://apilandscape.apiscene.io/
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
apidays
💥 You’re lucky! We’ve found two different (lead) developers that are willing to share their valuable lessons learned about using UiPath Document Understanding! Based on recent implementations in appealing use cases at Partou and SPIE. Don’t expect fancy videos or slide decks, but real and practical experiences that will help you with your own implementations. 📕 Topics that will be addressed: • Training the ML-model by humans: do or don't? • Rule-based versus AI extractors • Tips for finding use cases • How to start 👨🏫👨💻 Speakers: o Dion Morskieft, RPA Product Owner @Partou o Jack Klein-Schiphorst, Automation Developer @Tacstone Technology
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
UiPathCommunity
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows. We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases. This video focuses on the deployment of external web forms using Jotform for Bonterra Impact Management. This solution can be customized to your organization’s needs and deployed to support the common use cases below: - Intake and consent - Assessments - Surveys - Applications - Program registration Interested in deploying web form automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Jeffrey Haguewood
JAM, the future of Polkadot.
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Juan lago vázquez
💉💊+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHABI}}+971581248768 +971581248768 Mtp-Kit (500MG) Prices » Dubai [(+971581248768**)] Abortion Pills For Sale In Dubai, UAE, Mifepristone and Misoprostol Tablets Available In Dubai, UAE CONTACT DR.Maya Whatsapp +971581248768 We Have Abortion Pills / Cytotec Tablets /Mifegest Kit Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujairah, Ras Al Khaimah, Umm Al Quwain, UAE, Buy cytotec in Dubai +971581248768''''Abortion Pills near me DUBAI | ABU DHABI|UAE. Price of Misoprostol, Cytotec” +971581248768' Dr.DEEM ''BUY ABORTION PILLS MIFEGEST KIT, MISOPROTONE, CYTOTEC PILLS IN DUBAI, ABU DHABI,UAE'' Contact me now via What's App…… abortion Pills Cytotec also available Oman Qatar Doha Saudi Arabia Bahrain Above all, Cytotec Abortion Pills are Available In Dubai / UAE, you will be very happy to do abortion in Dubai we are providing cytotec 200mg abortion pill in Dubai, UAE. Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. We only offer abortion pills from 1 week-6 Months. We then advise you to use surgery if its beyond 6 months. Our Abu Dhabi, Ajman, Al Ain, Dubai, Fujairah, Ras Al Khaimah (RAK), Sharjah, Umm Al Quwain (UAQ) United Arab Emirates Abortion Clinic provides the safest and most advanced techniques for providing non-surgical, medical and surgical abortion methods for early through late second trimester, including the Abortion By Pill Procedure (RU 486, Mifeprex, Mifepristone, early options French Abortion Pill), Tamoxifen, Methotrexate and Cytotec (Misoprostol). The Abu Dhabi, United Arab Emirates Abortion Clinic performs Same Day Abortion Procedure using medications that are taken on the first day of the office visit and will cause the abortion to occur generally within 4 to 6 hours (as early as 30 minutes) for patients who are 3 to 12 weeks pregnant. When Mifepristone and Misoprostol are used, 50% of patients complete in 4 to 6 hours; 75% to 80% in 12 hours; and 90% in 24 hours. We use a regimen that allows for completion without the need for surgery 99% of the time. All advanced second trimester and late term pregnancies at our Tampa clinic (17 to 24 weeks or greater) can be completed within 24 hours or less 99% of the time without the need surgery. The procedure is completed with minimal to no complications. Our Women's Health Center located in Abu Dhabi, United Arab Emirates, uses the latest medications for medical abortions (RU-486, Mifeprex, Mifegyne, Mifepristone, early options French abortion pill), Methotrexate and Cytotec (Misoprostol). The safety standards of our Abu Dhabi, United Arab Emirates Abortion Doctors remain unparalleled. They consistently maintain the lowest complication rates throughout the nation. Our Physicians and staff are always available to answer questions and care for women in one of the most difficult times in their lives. The decision to have an abortion at the Abortion Cl
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
?#DUbAI#??##{{(☎️+971_581248768%)**%*]'#abortion pills for sale in dubai@
AXA XL - Insurer Innovation Award 2024
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
The Digital Insurer
Webinar Recording: https://www.panagenda.com/webinars/why-teams-call-analytics-is-critical-to-your-entire-business Nothing is as frustrating and noticeable as being in an important call and being unable to see or hear the other person. Not surprising then, that issues with Teams calls are among the most common problems users call their helpdesk for. Having in depth insight into everything relevant going on at the user’s device, local network, ISP and Microsoft itself during the call is crucial for good Microsoft Teams Call quality support. To ensure a quick and adequate solution and to ensure your users get the most out of their Microsoft 365. But did you know that ‘bad calls’ are also an excellent indicator of other problems arising? Precisely because it is so noticeable!? Like the canary in the mine, bad calls can be early indicators of problems. Problems that might otherwise not have been noticed for a while but can have a big impact on productivity and satisfaction. Join this session by Christoph Adler to learn how true Microsoft Teams call quality analytics helped other organizations troubleshoot bad calls and identify and fix problems that impacted Teams calls or the use of Microsoft365 in general. See what it can do to keep your users happy and productive! In this session we will cover - Why CQD data alone is not enough to troubleshoot call problems - The importance of attributing call problems to the right call participant - What call quality analytics can do to help you quickly find, fix-, and prevent problems - Why having retrospective detailed insights matters - Real life examples of how others have used Microsoft Teams call quality monitoring to problem shoot problems with their ISP, network, device health and more.
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
panagenda
Effective data discovery is crucial for maintaining compliance and mitigating risks in today's rapidly evolving privacy landscape. However, traditional manual approaches often struggle to keep pace with the growing volume and complexity of data. Join us for an insightful webinar where industry leaders from TrustArc and Privya will share their expertise on leveraging AI-powered solutions to revolutionize data discovery. You'll learn how to: - Effortlessly maintain a comprehensive, up-to-date data inventory - Harness code scanning insights to gain complete visibility into data flows leveraging the advantages of code scanning over DB scanning - Simplify compliance by leveraging Privya's integration with TrustArc - Implement proven strategies to mitigate third-party risks Our panel of experts will discuss real-world case studies and share practical strategies for overcoming common data discovery challenges. They'll also explore the latest trends and innovations in AI-driven data management, and how these technologies can help organizations stay ahead of the curve in an ever-changing privacy landscape.
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc
Join our latest Connector Corner webinar to discover how UiPath Integration Service revolutionizes API-centric automation in a 'Quote to Cash' process—and how that automation empowers businesses to accelerate revenue generation. A comprehensive demo will explore connecting systems, GenAI, and people, through powerful pre-built connectors designed to speed process cycle times. Speakers: James Dickson, Senior Software Engineer Charlie Greenberg, Host, Product Marketing Manager
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
DianaGray10
Tracing the root cause of a performance issue requires a lot of patience, experience, and focus. It’s so hard that we sometimes attempt to guess by trying out tentative fixes, but that usually results in frustration, messy code, and a considerable waste of time and money. This talk explains how to correctly zoom in on a performance bottleneck using three levels of profiling: distributed tracing, metrics, and method profiling. After we learn to read the JVM profiler output as a flame graph, we explore a series of bottlenecks typical for backend systems, like connection/thread pool starvation, invisible aspects, blocking code, hot CPU methods, lock contention, and Virtual Thread pinning, and we learn to trace them even if they occur in library code you are not familiar with. Attend this talk and prepare for the performance issues that will eventually hit any successful system. About authorWith two decades of experience, Victor is a Java Champion working as a trainer for top companies in Europe. Five thousands developers in 120 companies attended his workshops, so he gets to debate every week the challenges that various projects struggle with. In return, Victor summarizes key points from these workshops in conference talks and online meetups for the European Software Crafters, the world’s largest developer community around architecture, refactoring, and testing. Discover how Victor can help you on victorrentea.ro : company training catalog, consultancy and YouTube playlists.
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Victor Rentea
Three things you will take away from the session: • How to run an effective tenant-to-tenant migration • Best practices for before, during, and after migration • Tips for using migration as a springboard to prepare for Copilot in Microsoft 365 Main ideas: Migration Overview: The presentation covers the current reality of cross-tenant migrations, the triggers, phases, best practices, and benefits of a successful tenant migration Considerations: When considering a migration, it is important to consider the migration scope, performance, customization, flexibility, user-friendly interface, automation, monitoring, support, training, scalability, data integrity, data security, cost, and licensing structure Next Wave: The next wave of change includes the launch of Copilot, which requires businesses to be prepared for upcoming changes related to Copilot and the cloud, and to consolidate data and tighten governance ShareGate: ShareGate can help with pre-migration analysis, configurable migration tool, and automated, end-user driven collaborative governance
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
sammart93
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
The Digital Insurer
ICT role in 21 century education. How to ICT help in education
presentation ICT roal in 21st century education
presentation ICT roal in 21st century education
jfdjdjcjdnsjd
The microservices honeymoon is over. When starting a new project or revamping a legacy monolith, teams started looking for alternatives to microservices. The Modular Monolith, or 'Modulith', is an architecture that reaps the benefits of (vertical) functional decoupling without the high costs associated with separate deployments. This talk will delve into the advantages and challenges of this progressive architecture, beginning with exploring the concept of a 'module', its internal structure, public API, and inter-module communication patterns. Supported by spring-modulith, the talk provides practical guidance on addressing the main challenges of a Modultith Architecture: finding and guarding module boundaries, data decoupling, and integration module-testing. You should not miss this talk if you are a software architect or tech lead seeking practical, scalable solutions. About the author With two decades of experience, Victor is a Java Champion working as a trainer for top companies in Europe. Five thousands developers in 120 companies attended his workshops, so he gets to debate every week the challenges that various projects struggle with. In return, Victor summarizes key points from these workshops in conference talks and online meetups for the European Software Crafters, the world’s largest developer community around architecture, refactoring, and testing. Discover how Victor can help you on victorrentea.ro : company training catalog, consultancy and YouTube playlists.
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Victor Rentea
Kürzlich hochgeladen
(20)
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
presentation ICT roal in 21st century education
presentation ICT roal in 21st century education
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Vital Signs Edition #6
1.
Jetzt herunterladen